AAD
  • Meeting Program
  • Registration
  • Daily Coverage
  • Photo Gallery
  • Samples & Solutions
Topics
  • Daily Coverage
  • Photo Gallery
  • Samples & Solutions
Resources
  • Meeting Program
  • Registration
Facebook iconInstagram iconTwitter X icon
Mar 10, 2024

Pearls from both sides of the pond

American and European dermatologists share news on upcoming treatments.


Headshot of Jeffrey Callen, MD, FAAD, FACP, MACR
Jeffrey Callen, MD, FAAD, FACP, MACR

S059 – The Best of American and European Dermatology
1-4 p.m. | Monday, March 11
Location: Room 6F

Pustular psoriasis is a rare, but serious condition. The good news for dermatologists and their patients is that there are at least two new treatments in the pipeline for pustular psoriasis and other conditions, which may change the way they are managed in the near future.

Jeffrey Callen, MD, FAAD, FACP, MACR, professor of medicine and chief of the division of dermatology at the University of Louisville School of Medicine in Kentucky, said intravenous spesolimab has been approved as a treatment for generalized pustular psoriasis, but it may have even more uses than that. Dr. Callen is the director of Monday’s session, S059 – The Best of American and European Dermatology.

“It might eventually be approved as an SQ injection for pustular psoriasis of the palms and soles,” Dr. Callen said.

Shared concerns

Other treatments currently being studied include bimekizumab for pustular psoriasis of the palms and soles, nemolizumab for prurigo nodularis, dupilumab for bullous pemphigoid, and mogamulizimab for cutaneous T-cell lymphoma.

The session will also feature a discussion of these treatments and others for multiple conditions, including:

  • Blistering diseases
  • Chronic urticaria
  • Cutaneous T-cell lymphoma
  • Hidradenitis
  • Itching
  • Pustular psoriasis

Dr. Callen, working with Michel F. Gilliet, MD, the European Academy of Dermatology and Venereology (EADV) representative, said these topics were selected because they are relevant in both Europe and the United States.

“But our approaches to evaluation and management might differ,” Dr. Callen said. “There are excellent researchers on both sides of the Atlantic, and we specifically selected these topics as they have new options for therapy that are currently approved or will likely be approved in the near future.”

A good fit

Dr. Callen said the AAD has always worked closely with its European counterpart, the EADV, to facilitate the exchange of ideas and research between European and American dermatologists. In fact, that partnership dates back to the formation of the EADV in 1987.

“When [the EADV] was formed, it based its annual meeting format largely on the use of the format of the AAD’s Annual Meeting,” Dr. Callen said.

In the spirit of cooperation, Dr. Callen said the AAD suggested having a joint session with the two organizations at each other’s meetings to better help each association’s members understand what was going on across the pond and gain new perspectives on various conditions they were seeing.

“Initially, the AAD session was held during the AAD’s summer meeting, but in the last five or so years, the AAD session was moved to the Annual Meeting,” Dr. Callen said. “Each organization has a member or committee that suggests three speakers annually for each session after assessing what appears to be the hot topics.”

Other topics and speakers at tomorrow’s globally inspired session include a lecture on chronic spontaneous urticaria; pruritus by Shawn Kwatra, MD, FAAD; hidradenitis suppurativa by Robert Micheletti, MD, FAAD; a presentation on cutaneous T-cell lymphoma; immunobullous diseases by John Joseph Zone, MD, FAAD; and pustular psoriasis by Jonathan Barker, MD.

Interesting Stories
DermWorld March | Publishing profiteers
Presented by AAD
DermWorld March | Publishing profiteers
Dermworld June | Smoke and the skin
Presented by AAD
Dermworld June | Smoke and the skin
DermWorld  January | Scar solutions
Presented by AAD
DermWorld January | Scar solutions
DermWorld May | Deciding the right time for treatment
Presented by AAD
DermWorld May | Deciding the right time for treatment
DermWorld April | Shedding light on treatments for female pattern hair loss
Presented by AAD
DermWorld April | Shedding light on treatments for female pattern hair loss
DermWorld February | Glow Up
Presented by AAD
DermWorld February | Glow Up
More in 2024 AAD Annual Meeting
Dsc01534
2024 AAD Annual Meeting
Stellar, inspiring, motivating, and mind-blowing!
Apr 12, 2024
Valerie Callender, MD, FAAD
2024 AAD Annual Meeting
Healing for all skin types
Apr 12, 2024
Posters Crowd2 Web
2024 AAD Annual Meeting
Poster awards announced!
Apr 12, 2024
A debate panel offered a look inside the challenges of caring for patients with medical dermatology disease.
2024 AAD Annual Meeting
Challenges, complexities, and dilemmas
Apr 12, 2024
Katharina Stephanie Shaw, MD, FAAD
2024 AAD Annual Meeting
Preparing for baby
Apr 12, 2024
Alexandra Flamm, MD, FAAD
2024 AAD Annual Meeting
Three elements of effective practice management
Apr 12, 2024
Marta J. Van Beek, MD, MPH, FAAD
2024 AAD Annual Meeting
A one-two punch for generalized pustular psoriasis (GPP)
Apr 12, 2024
Panelists present AAD session.
2024 AAD Annual Meeting
“Missed” diagnosis
Mar 18, 2024
Anisha Patel sits at table.
2024 AAD Annual Meeting
New cancer drugs can cause severe skin reactions
Mar 18, 2024
Professional headshot of Dr. Raj Chovatiya
2024 AAD Annual Meeting
A compendium of itch
Mar 18, 2024
Panel of four dermatologists presenting at AAD session.
2024 AAD Annual Meeting
Can we talk about it?
Mar 18, 2024
Robert Bissonnette delivers presentation at podium
2024 AAD Annual Meeting
From hands to feet
Mar 18, 2024
AAD
Facebook iconInstagram iconTwitter X icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.